🔎 Trials Near Me

Beranda › Kanker Kolorektal › Nebraska › Omaha

Uji klinis Kanker Kolorektal di Omaha, NE

18 studi untuk Kanker Kolorektal mencari peserta di lokasi sekitar Omaha (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

Family Communications After Genetic Testing

Menerima pesertaSukarelawan sehat diterima
  • Alegent Health Immanuel Medical Center, Omaha
  • Alegent Health Bergan Mercy Medical Center, Omaha
  • Alegent Health Lakeside Hospital, Omaha
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07143487

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

Menerima pesertaFase 2
  • Nebraska Medicine-Village Pointe, Omaha
  • University of Nebraska Medical Center, Omaha
  • Nebraska Medicine-Bellevue, Bellevue · 9 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05673148

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Menerima pesertaStudi observasionalSukarelawan sehat diterima
  • Alegent Health Immanuel Medical Center, Omaha
  • Alegent Health Bergan Mercy Medical Center, Omaha
  • Alegent Health Lakeside Hospital, Omaha
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Menerima pesertaFase 1
  • Exelixis Clinical Site #2, Omaha
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT05176483

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

Menerima pesertaFase 1/2
  • Nebraska Cancer Specialists, Omaha
  • XCancer, Omaha
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07189871

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

Menerima pesertaFase 2
  • Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271646, Omaha
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06820463

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

Menerima pesertaFase 3
  • Nebraska Cancer Specialists, Omaha
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06750094

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Menerima pesertaFase 3
  • Nebraska Cancer Specialists Midwest Cancer Center, Omaha
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06662786

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Menerima pesertaFase 1/2
  • Nebraska Cancer Specialists, Omaha
  • University of Nebraska Medical Center, Omaha
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06445062

Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease

Menerima pesertaFase 3
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists - Methodist, Omaha
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists - Bergan, Omaha
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists - Legacy, Omaha
  • dan 2 lainnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT07750158

A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)

Menerima pesertaFase 1
  • Nebraska Cancer Specialists, Omaha
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT07416552

Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy

Menerima pesertaFase 2
  • Nebraska Cancer Specialists, Omaha
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Jul 2026 · NCT06937177

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Menerima pesertaFase 1/2
  • Nebraska Cancer Specialists, Omaha
Usia 18 hingga 90 · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT06710756

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Menerima pesertaFase 1
  • Nebraska Cancer Specialists (Midwest Cancer Center - Legacy), Omaha
  • XCancer Omaha / Urology Cancer Center, Omaha
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Jun 2026 · NCT05283330

Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors

Menerima pesertaFase 3Sukarelawan sehat diterima
  • Alegent Health Immanuel Medical Center, Omaha
  • Alegent Health Bergan Mercy Medical Center, Omaha
  • Alegent Health Lakeside Hospital, Omaha
  • dan 1 lainnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Mar 2026 · NCT07018869

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

Menerima pesertaFase 1/2
  • Nebraska Cancer Specialists, Omaha
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Feb 2026 · NCT07030257

Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

Menerima pesertaStudi observasional
  • Nebraska Cancer Specialists, Omaha
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Mei 2025 · NCT05234177

Uji klinis Kanker Kolorektal di kota lain

Studi lain di Omaha

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.